Back
TC Biopharm (Holdings) PLC (TCBPY) Earnings
TCBPY Stock Price Chart
TCBPY Earnings
TC Biopharm (Holdings) PLC
$0.01
0%
$0
At close: Mar 26, 16:00:00 GMT-4
$0.01
0%
$0
Pre-market: Mar 27, 04:05:17 GMT-4
No Data YetEarnings FAQ
How did TCBPY's recent EPS compare to expectations?
How did TC Biopharm (Holdings) PLC TCBPY's revenue perform in the last quarter?
What is the revenue estimate for TC Biopharm (Holdings) PLC?
What's the earning quality score for TC Biopharm (Holdings) PLC?
When does TC Biopharm (Holdings) PLC report earnings?
What are TC Biopharm (Holdings) PLC's expected earnings?
Did TC Biopharm (Holdings) PLC beat earnings expectations?
Key Stats
Prev.Close
$0.018
Open
$0.041
Day's Range
$0.018 - $0.041
52 week range
$0.017 - $0.69
Volume
31.2K
Avg.Volume
13.7K
Dividend yield
--
EPS (TTM)
-7.34
Market Cap
$184.6K
What is TCBPY?
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.
Features
Resources
© 2026 Finture Development Limited. All rights reserved